Contribute Try STAT+ Today

Top of the morning, and a fine one it is. Clear blue skies and crisp breezes are enveloping the Pharmalot campus this morning where our short person remains fixated on a laptop and our official mascot has a doggie playdate (yes, this is a thing). As for us, we are busy doing the usual — brewing cups of stimulation and focusing on our to-do list. Perhaps you relate. On that note, here are a few items of interest to help you get going. We hope you meet your goals today, or at least fulfill a few desires. Meanwhile, stay safe and stay in touch. …

Two top executives of Emergent BioSolutions (EBS), whose Baltimore plant ruined millions of doses of Covid-19 vaccine, have agreed to testify on Capitol Hill next week as part of a congressional investigation into their company, a politically connected federal contractor, The New York Times writes. The panel has opened a sprawling inquiry into the manufacturing failures, and whether the company used its contacts with the Trump administration to land hundreds of millions of dollars in coronavirus vaccine contracts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.